Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Chinese PLA General Hospital (CAR-T cell technology)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Biologic cancer therapy asset. The asset consists of Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and human epidermal growth factor receptor's immuno-oncology patents, and phase I/II clinical data of the therapies and manufacturing knowledge. The CAR-T cell therapy involves engineering cancer patients' own immune cells to recognize and attack their tumors.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
  • 28 fuxing road
  • Beijing
  • China

Chinese PLA General Hospital (CAR-T cell technology) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.

Request full access to PitchBook

Chinese PLA General Hospital (CAR-T cell technology) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.

Request full access to PitchBook